Trial Profile

A Phase 1 Study of Venetoclax in Combination with Inotuzumab Ozogamicin for B-cell Acute Lymphoblastic Leukemia (B-ALL)

Status: Recruiting

Phase of Trial: Phase I

Latest Information Update: 28 Jan 2025

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Dexamethasone (Primary) ; Inotuzumab ozogamicin (Primary) ; Venetoclax (Primary)
Indications Chronic myeloid leukaemia; Precursor B-cell lymphoblastic leukaemia-lymphoma
Focus Adverse reactions

Most Recent Events

23 Jan 2025 Planned primary completion date changed from 23 Dec 2024 to 23 Dec 2025.
14 Aug 2024 Planned primary completion date changed from 23 Jul 2024 to 23 Dec 2024.
12 Dec 2023 Results for safety and efficacy, presented at the 65th American Society of Hematology Annual Meeting and Exposition

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com